Phase 3 Study of Insulin Degludec for Type 2 Diabetes

Novo Nordisk announced results from a Phase 3 study of its investigational ultra-long-acting insulin degludec. The insulin significantly reduced the rate of hypoglycemia at night in adults with type 2 diabetes while obtaining equivalent improvement in glucose control compared with insulin glargine (Lantus; Sanofi Aventis) over a 52-week period. The study also found that insulin degludec had significantly lower rates of severe hypoglycemia compared to insulin glargine.